Cantargia

KEY DATA

Sweden Stock country **CANTA SS** Bloombera Reuters CANTA.ST Share price (close) SEK 18.44 Free Float Market cap. (bn) EUR 0.12/SEK 1.22 Website http://cantargia.com/ Next report date 27 Feb 2020

78%

PERFORMANCE 24 21 18 15 12 Cantargia Source: Thomson Reuters Sweden OMX Stockholm All-Share (Rebased)

VALUATION APPROACH DCF SEK 27 SEK 24 10 20 30 40 Source: Nordea estimates

ESTIMATE CHANGES										
Year	2019E	2020E	2021E							
Sales	0%	34%	n.a.							
EBIT (adj)	0%	39%	0%							

Source: Nordea estimates

Nordea Markets - Analysts Klas Pyk Analyst

Promising interim data from combination study

Cantargia has published positive interim data from the ongoing ph IIa study for CAN04. In total, ten patients (seven with metastatic pancreatic cancer and three with metastatic non-small cell lung cancer) have been evaluated, showing promising data, particularly for pancreatic cancer. Despite the small number of patients, we are encouraged by the results, and we raise our fair valuation range to SEK 24-27 (19-22) per share.

Encouraging results warrant interim release

On 2 November, Cantargia presented interim data from the ongoing ph IIa combination study for CAN04. While the top-line results from the combination study are expected in H1 2020, the interim data was encouraging enough to warrant an early release.

Partial response for 4 out of 7 evaluated patients with PDAC

The interim results show that four out of seven evaluated patients (57%) with metastatic pancreatic cancer (PDAC) demonstrated partial response to the treatment. This should be compared to the historical response rates of the investigated chemotherapies, which are 23% in PDAC, indicating that response rates increase from adding CAN04. Furthermore, three PDAC patients showed more than a 90% decrease in CA19-9, a biomarker for pancreatic cancer tumour burden (historically, a >90% reduction has been reported in 31% of PDAC patients after gemcitabine/abraxane therapy). Three NSCLC patients were also evaluated, of which one had a confirmed complete response and one a partial response.

Higher likelihood of positive phase IIa results

Although these are interim results and the number of patients is limited, we are encouraged by the high response rates. As such, we raise the likelihood of a positive outcome in the CAN04 ph IIa study to 50% (from 28%) for pancreatic cancer, implying a probability of reaching the market of ~9% (~12% for NSCLC). As such, we raise our fair valuation range to SEK 24-27 (19-22). Further upside is, however, warranted if the full phase IIa trial proves successful (expected in H1 2020).

SUMMARY TABLE - KEY FIGURES										
SEKm	2015	2016	2017	2018	2019E	2020E	2021E			
Total revenue	0	0	0	0	0	780	0			
EBITDA (adj)	-17	-48	-60	-93	-101	706	-74			
EBIT (adj)	-17	-48	-60	-93	-101	706	-74			
EBIT (adj) margin	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.			
EPS (adj)	-1.27	-2.27	-1.28	-1.38	-1.38	9.74	-0.85			
EPS (adj) growth	-15.5%	-78.4%	43.5%	-7.3%	0.0%	807.1%	-108.7%			
DPS (ord)	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
EV/Sales	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.			
EV/EBIT (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.			
P/E (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	1.9	n.m.			
P/BV	n.a.	n.a.	1.2	6.1	8.7	1.6	1.7			
Dividend yield (ord)	n.a.	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%			
FCF Yield bef A&D, lease	n.a.	n.a.	-13.7%	-11.1%	-6.9%	48.4%	-1.7%			
Net debt	-25	-35	-270	-167	-174	-824	-801			
Net debt/EBITDA	1.4	0.7	4.5	1.8	1.7	-1.2	10.8			
ROIC after tax	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.			

Source: Company data and Nordea estimates

Reported numbers and forecasts

INCOME STATEMENT											
SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
Total revenue	n.a.	n.a.	0	0	0	0	0	0	0	780	(
Revenue growth	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	-100.0%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
EBITDA	0	0	-8	-8	-17	-48	-60	-93	-101	706	-74
Depreciation and impairments PPE	0	0	0	0	0	0	0	0	0	0	C
of which leased assets	0	0	0	0	0	0	0	0	0	0	C
EBITA	0	0	-8	-8	-17	-48	-60	-93	-101	706	-74
Amortisation and impairments	0	0	0	0	0	0	0	0	0	0	C
EBIT	n.a.	n.a.	-8	-8	-17	-48	-60	-93	-101	706	-74
of which associates	0	0	0	0	0	0	0	0	0	0	C
Associates excluded from EBIT	0	0	0	0	0	0	0	0	0	0	C
Net financials	0	0	0	0	0	0	0	2	1	3	12
of which lease interest	0	0	0	0	0	0	0	0	0	0	C
Changes in value, net	0	0	0	0	0	0	0	0	0	0	C
Pre-tax profit	0	0	-8	-8	-17	-47	-60	-91	-100	709	-62
Reported taxes	0	0	0	0	0	0	0	0	0	0	C
Net profit from continued operations	0	0	-8	-8	-17	-47	-60	-91	-100	709	-62
Discontinued operations	0	0	0	0	0	0	0	0	0	0	C
Minority interests	0	0	0	0	0	0	0	0	0	0	Ċ
Net profit to equity	0	0	-8	-8	-17	-47	-60	-91	-100	709	-62
EPS EPS	n.a.	n.a.	-1.25	-1.10	-1.27	-2.27	-1.28	-1.38	-1.38	9.74	-0.85
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
or whom over dorainary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit margin in percent											
EBITDA	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.
EBITA	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.
EBIT	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.
Adjusted earnings											
EBITDA (adj)	0	0	-8	-8	-17	-48	-60	-93	-101	706	-74
EBITA (adj)	0	0	-8	-8	-17	-48	-60	-93	-101	706	-74
EBIT (adj)	0	0	-8	-8	-17	-48	-60	-93	-101	706	-74
EPS (adj)	n.a.	n.a.	-1.25	-1.10	-1.27	-2.27	-1.28	-1.38	-1.38	9.74	-0.85
_ (==)/											
Adjusted profit margins in percent											
EBITDA (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.
EBITA (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.
EBIT (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	90.5%	n.m.
(j)											
Performance metrics											
CAGR last 5 years											
Net revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
EPS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
DPS	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Average last 5 years											
Average EBIT margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	51.8%	48.4%
Average EBITDA margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	51.8%	48.4%
VALUATION BATIOS AD ILISTED I											
VALUATION RATIOS - ADJUSTED I											
SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
P/E (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	1.9	n.m.
EV/EBITDA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.
EV/EBITA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.
EV/EBIT (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.
VALUATION RATIOS - REPORTED	EARNING	iS									
SEKm	2011	2012	2012	2014	2015	2046	2017	2040	2019E	2020E	2021E
P/E			2013	2014		2016		2018			
	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	1.9	n.m.
EV/Sales	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.67	n.m.
EV/EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.
EV/EBITA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.
EV/EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	0.7	n.m.
Dividend yield (ord.)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-13.7%	-11.1%	-6.9%	48.4%	-1.7%
FCF Yield bef A&D, lease adj	n.a.	n.a.	n.a.	n.a.	n.a. 0.0%	n.a. 0.0%	-13.7% 0.0%	-11.1% 0.0%	-6.9%	48.4%	-1.7%
Payout ratio	n.a.	n.a.	0.0%	0.0%					0.0%	0.0%	0.0%

Source: Company data and Nordea estimates

Intangible assets	BALANCE SHEET											
of winch RAD	SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
of which other intangibles	Intangible assets	0	1			0	0	0	0	0	0	C
of which goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	of which R&D	0	1	2	2	0	0	0	0	0	0	0
Tangible assets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
of which leased assets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Shares associates 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Interest bearing assets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Deferred tax assets		-				_				-		0
Other non-current assets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Other non-current assets 0 0 0 0 2 3 3 3 0 0 Total non-current assets 0 1 2 3 3 3 0 0 Inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Total non-current assets												0
Inventory										_		0
Accounts receivable												0
Short-term leased assets												0
Other current assets 0 0 1 1 1 2 2 2 0 39 Cash and bank 0 3 1 17 25 35 270 167 174 824 8 Total current assets 0 3 2 177 25 37 271 168 184 980 8 Assets held for sale 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Cash and bank												0
Total current assets 0 3 2 17 25 37 271 168 184 980 8 Assets held for sale 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Assets held for sale												801
Total assets												801
Shareholders equity 0 3 3 3 4 24 30 246 155 154 863 8 O' which preferred stocks 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0 801
Of which preferred stocks 0 0 0 0 0 0 0 0 0 0 0 99 99 Of which equity part of hybrid debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total assets	U	4	4	20	21	40	2/4	1/1	184	980	801
Of which equity part of hybrid debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Shareholders equity	0	3	3	4	24	30	246	155	154	863	801
Minority interest	Of which preferred stocks	0	0	0	0	0	0	0	0	99	99	99
Total Equity 0 3 3 3 4 24 30 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 246 155 154 863 8 20 245 164 264 264 26 245 160 2 245 164 245 49 8 245 49 8 245 49 8 20 24 145 245 49 8 245 49 8 245 49 8 245 49 8 245 49 8 245 49 8 20 2 1 1.4 0.7 4.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2 10 164 261 170 A 2.5 1.8 1.7 -1.2	Of which equity part of hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Deferred tax	Minority interest	0	0	0	0	0	0	0	0	0	0	0
Long term interest bearing debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total Equity	0	3	3	4	24	30	246	155	154	863	801
Pension provisions	Deferred tax	0	0	0	0	0	0	0	0	0	0	0
Other long-term provisions 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 </td <td>Long term interest bearing debt</td> <td>0</td>	Long term interest bearing debt	0	0	0	0	0	0	0	0	0	0	0
Other long-term liabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0<	Pension provisions	0	0	0	0	0	0	0	0	0	0	0
Non-current lease debt	Other long-term provisions	0	0		0	0	0	0	0	0	0	0
Convertible debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0										_		0
Shareholder debt												0
Hybrid debt												0
Total non-current liabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Short-term provisions												0
Accounts payable 0 0 1 1 1 2 7 21 9 12 78 Current lease debt 0 0 0 0 0 0 0 0 0 0 0 0 0 Other current liabilities 0 0 0 0 15 1 2 8 7 18 39 Short term interest bearing debt 0 0 0 0 0 0 0 0 0 0 0 0 0 Total current liabilities 0 1 1 1 16 3 10 28 16 30 117 Liabilities for assets held for sale 0 0 0 0 0 0 0 0 0 0 0 0 0 Total liabilities and equity 0 4 4 20 27 40 274 171 184 980 8 Balance sheet and debt metrics Net debt 0 0 3 -3 -1 -17 -25 -35 -270 -167 -174 -824 -8 of which lease debt 0 0 0 0 0 0 0 0 0 0 0 0 Working capital 0 0 0 0 -15 -2 -7 -27 -15 -20 39 Invested capital 0 0 0 2 -13 -1 -5 -24 -12 -20 39 Capital employed 0 3 3 3 4 24 30 246 155 154 863 8 ROE n.m. 0.0% n.m. n.m. n.m. n.m. n.m. n.m. n.m. n.m												0
Current lease debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	•									-		0
Other current liabilities 0 0 0 15 1 2 8 7 18 39 Short term interest bearing debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Short term interest bearing debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <												0
Total current liabilities 0 1 1 1 16 3 10 28 16 30 117 Liabilities for assets held for sale 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Total liabilities and equity 0 4 4 20 27 40 274 171 184 980 8 Balance sheet and debt metrics Net debt 0 -3 -1 -17 -25 -35 -270 -167 -174 -824 -8 of which lease debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Working capital 0 0 0 0 -15 -2 -7 -27 -15 -20 39 Invested capital 0 0 0 2 -13 -1 -5 -24 -12 -20 39 Invested capital 0 0 3 3 4 24 30 246 155 154 863 8 ROE n.m. 0.0% n.m. n.m. n.m. n.m. n.m43.6% -45.4% -64.9% n.m7.4 ROIC n.m. 0.0% n.m. n.m. n.m. n.m. n.m. n.m. n.m. n.m												0
Liabilities for assets held for sale 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												0
Balance sheet and debt metrics Net debt of which lease debt 0 -3 -1 -17 -25 -35 -270 -167 -174 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -824 -924 -927 -155 -227 -155 -227 -155 -220 39 -924 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124 -124<												0
Balance sheet and debt metrics Net debt 0 -3 -1 -17 -25 -35 -270 -167 -174 -824 -8 of which lease debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 39 1 1.7 -2.7 -15 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0 39 -2.0												0
Net debt 0 -3 -1 -17 -25 -35 -270 -167 -174 -824 -824 -824 -824 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182 -182<	lotal liabilities and equity	U	4	4	20	27	40	274	171	184	980	801
Net debt 0 -3 -1 -17 -25 -35 -270 -167 -174 -824 -8 of which lease debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 39 1 1 -5 -24 -12 -20 39 1 1 -5 -24 -12 -20 39 1 1 -5 -24 -12 -20 39 1 1 -5 -24 -12 -20 39 1 1 -5 -24 -12 -20 39 1 1 -5 -24 -12 -20 39 1 1 -6 -24 -12 -20 39 1 1 -6 -8 1 863 8 8 <	Balance sheet and debt metrics											
of which lease debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 3 1 2 2 4 -12 -20 39 2 -13 -1 -5 -24 -12 -20 39 2 -20 39 -20 39 -20 39 -20 39 -20 39 -24 -12 -20 39 -20 39 -24 -12 -20 39 -20 39 -24 -12 -20 39 -24 -24 30 246 155 154 863 8 8		0	-3	-1	-17	-25	-35	-270	-167	-174	-824	-801
Working capital 0 0 0 -15 -2 -7 -27 -15 -20 39 Invested capital 0 0 2 -13 -1 -5 -24 -12 -20 39 Capital employed 0 3 3 4 24 30 246 155 154 863 8 ROE n.m. 0.0% n.m. n.m. n.m. n.m. -43.6% -45.4% -64.9% n.m. -7.4 ROCE n.m. 0.0% n.m. n.m. n.m. n.m. n.m. n.m. -13.4 0.7 4.5 1.8 1.7 -1.2 11 Net debt/EBITDA n.a. n.a. n.m. n.m. <td></td> <td>0</td> <td></td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td></td> <td>0</td>		0		0	0				0	0		0
Invested capital 0												0
Capital employed 0 3 3 4 24 30 246 155 154 863 8 ROE n.m. 0.0% n.m. n.m. n.m. n.m. -43.6% -45.4% -64.9% n.m. -7.4 ROIC n.m. 0.0% n.m. -43.4% -45.4% -64.9% n.m. -7.4 Net debt/EBITDA n.m. n.m. 0.2 2.1 1.4 0.7 4.5 1.8 1.7 -1.2 10 Interest coverage n.a. n.m.	. .	0		2								0
ROE n.m. 0.0% n.m. n.m. n.m. n.m. n.m. -43.6% -45.4% -64.9% n.m. -7.4 ROIC n.m. 0.0% n.m. -43.4% -45.4% -64.9% n.m. n.m. -7.4 Net debt/EBITDA n.m. n.m. 0.2 2.1 1.4 0.7 4.5 1.8 1.7 -1.2 11 Interest coverage n.a. n.m.	•	0	3	3	4	24	30	246	155	154	863	801
ROIC n.m. 0.0% n.m. n.m. <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-7.4%</td></th<>												-7.4%
ROCE n.m. 0.0% n.m. n.m. n.m. n.m. -43.4% -45.4% -64.9% n.m. -7.4 Net debt/EBITDA n.m. n.m. 0.2 2.1 1.4 0.7 4.5 1.8 1.7 -1.2 10 Interest coverage n.a. n.m. n.m. </td <td></td> <td>n.m.</td>												n.m.
Interest coverage n.a. n.a. n.m. n.m. n.m. n.m. n.m. n.m.	ROCE											-7.4%
Interest coverage n.a. n.a. n.m. n.m. n.m. n.m. n.m. n.m.	Not dobt/ERITDA	n	p	0.0	0.4	4.4	0.7	4 -	4.0	4 7	4.0	40.0
												10.8
Lyuny rano 11.111. 01.070 10.070 20.470 00.070 10.070 09.170 90.470 80.170 80.170 100.0												n.m.
												-100.0%

Source: Company data and Nordea estimates

CASH FLOW STATEMENT											
SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
EBITDA (adj) for associates	0	0	-8	-8	-17	-48	-60	-93	-101	706	-74
Paid taxes	0	0	0	0	0	0	0	0	0	0	0
Net financials	0	0	0	0	0	0	0	0	1	3	12
Change in provisions	0	0	0	0	0	0	0	0	0	0	0
Change in other LT non-IB	0	0	0	0	-1	-1	0	0	3	0	0
Cash flow to/from associates	0	0	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	0	0	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	0	0	0	0	1	1	0	0	0	0	0
Funds from operations (FFO)	0	0	-8	-8	-17	-47	-60	-93	-97	709	-62
Change in NWC	0	0	0	15	-13	5	19	-12	5	-59	39
Cash flow from operations (CFO)	0	0	-8	7	-30	-42	-41	-105	-92	650	-23
Capital expenditure	0	0	0	0	0	0	0	0	0	0	0
Free cash flow before A&D	0	0	-8	7	-30	-42	-41	-105	-92	650	-23
Proceeds from sale of assets	0	0	0	0	0	0	0	0	0	0	0
Acquisitions	0	0	0	0	0	0	0	0	0	0	0
Free cash flow	0	0	-8	7	-30	-42	-41	-105	-92	650	-23
Free cash flow bef A&D, lease adj	0	0	-8	7	-30	-42	-41	-105	-92	650	-23
Dividends paid	0	0	0	0	0	0	0	0	0	0	0
Equity issues / buybacks	0	0	8	10	45	56	304	0	99	0	0
Net change in debt	0	0	0	0	0	0	0	0	0	0	0
Other financing adjustments	0	0	0	0	0	0	0	30	0	0	0
Other non-cash adjustments	0	3	-1	-1	-7	-4	-28	-28	0	0	0
Change in cash	0	3	-1	15	8	10	235	-103	7	650	-23
Cash flow metrics											
Capex/D&A	n.m.	n.m.	n.m.								
Capex/Sales	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	0.0%	0.0%	n.m.
Key information											
Share price year end (/current)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	6	14	18	18	18
Market cap.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	300	940	1,343	1,343	1,343
Enterprise value	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	31	773	1,169	519	541
Diluted no. of shares, year-end (m)	0.0	0.0	6.3	7.6	13.5	20.9	46.9	66.2	72.8	72.8	72.8

Diluted no. of shares, year-end (m)
Source: Company data and Nordea estimates

Disclaimer and legal disclosures

Origin of the report

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their unit Nordea Markets.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authorities in their respective countries.

Content of report

This report has been prepared solely by Nordea Markets.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets ("External Information"), Nordea Markets has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interes

Readers of this document should note that Nordea Markets has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report.

Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea Markets that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at www.nordea.com/miffd.

Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US. This research report is intended only for, and may be distributed only to, accredited investors, expert investors or institutional investors in Singapore who may contact Nordea Bank, Singapore Branch of 138 Market Street, #09-01 CapitaGreen, Singapore 048946.

This report may be distributed by Nordea Bank Luxembourg S.A., 562 rue de Neudorf, L-2015 Luxembourg which is subject to the supervision of the Commission de Surveillance du Secteur Financier.

This publication or report may be distributed by Nordea Bank Abp Singapore Branch, which is subject to the supervision of the European Central Bank, the Finnish Financial Supervisory Authority and the Monetary Authority of Singapore.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanssivalvonta (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

Analyst Shareholding

Nordea Markets analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates

Fair value sensitivity

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. When applicable, we set a 12-month target price by applying an appropriate premium/discount and/or other relevant adjustment to our fair value to reflect the share price potential we see within the coming 12 months. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of

capital are typically the most sensitive.
It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. Dividend payouts are included in the target price. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

Marketing Material

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Where applicable, recommendation changes are available at: https:// research.nordea.com/compliance#equity-changes.

Market-making obligations and other significant financial interest

Nordea Markets has no market-making obligations in Cantargia.

Investment banking transactions

In view of Nordea's position in its markets readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services to the company/companies

Issuer Review

This report has not been reviewed by the Issuer prior to publication.

Completion Date

04 Dec 2019, 01:33 CET

Nordea Bank Abp	Nordea Bank Abp, filial i Sverige	Nordea Danmark, Filial af Nordea Bank Abp, Finland	Nordea Bank Abp, filial i Norge
Nordea Markets Division,	Nordea Markets Division,	Nordea Markets Division,	Nordea Markets Division,
Research	Research	Research	Research
Visiting address:	Visiting address:	Visiting address:	Visiting address:
Aleksis Kiven katu 7, Helsinki	Smålandsgatan 17	Grønjordsvej 10	Essendropsgate 7
FI-00020 Nordea	SE-105 71 Stockholm	DK-2300 Copenhagen S	N-0107 Oslo
Finland	Sweden	Denmark	Norway
Tel: +358 9 1651	Tel: +46 8 614 7000	Tel: +45 3333 3333	Tel: +47 2248 5000
Fax: +358 9 165 59710	Fax: +46 8 534 911 60	Fax: +45 3333 1520	Fax: +47 2256 8650
Reg.no. 2858394-9			
Satamaradankatu 5			

Helsinki